-

Viz.ai Launches Viz 3D CTA™ to Deliver Enhanced Imaging and Accelerate Clinical Decision-Making

New feature provides AI-enhanced 3D imaging to improve neurovascular visualization and streamline workflows

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz 3D CTA, a new solution that automatically converts computed tomography angiography (CTA) scans into high-resolution, AI-enhanced 3D images for faster and clearer neurovascular visualization. Fully integrated into the Viz.ai platform, this capability enables care teams to interact with complex neurovascular anatomy in real-time — automatically removing bone and venous structures to enhance clarity and support time savings in stroke and aneurysm workflows.

“Viz 3D CTA gives me a clearer, faster view of what’s going on. Being able to rotate the image and see vessels from different angles makes a big difference, especially in tricky areas,” said Benjamin Alwood, MD, neurologist at UF Health Jacksonville. “It’s also a great safety net for spotting occlusions that might otherwise be missed. Having this kind of clarity right away helps me make quicker, more confident decisions.”

Viz 3D CTA addresses challenges in neurovascular imaging, including delays due to manual 3D renderings, limited spatial context in PACS, and difficulty viewing smaller or more distal vessel abnormalities. With automated post-processing, skull-stripped views, and interactive tools — including sagittal and axial rotation — Viz 3D CTA offers clinicians a dynamic, full-brain perspective within minutes.

“With Viz 3D CTA, we’re extending the Viz.ai One® platform with a powerful imaging tool that enables clearer, faster decisions in neurovascular care,” said Prem Batchu-Green, VP of Care Pathways, Value and Success at Viz.ai. “We are proud to bring this capability directly into the hands of providers who are working to save lives and preserve function every day.”

Viz 3D CTA is now available to hospitals and health systems on the Viz.ai One platform, which is deployed in over 1,700 hospitals and health systems. To learn more about Viz 3D CTA, visit viz.ai/neuro.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.

Contacts

Media Contacts
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Viz.ai, Inc.


Release Versions

Contacts

Media Contacts
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Social Media Profiles
More News From Viz.ai, Inc.

Viz.ai Receives First and Only FDA 510(k) Clearance for Subdural Measurements

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz Subdural Plus, the first and only comprehensive solution for quantifying the size of collections like subdural hemorrhages (SDH) in the subdural space on non-contrast computed tomography (NCCT) images. The Viz Subdural Plus module is designed to support clinical-decision making by au...

New Study Demonstrates AI-Powered Care Coordination Reduces Transfer Time and Improves Outcomes in Intracerebral Hemorrhage Patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data showcasing the impact of Viz ICH and Viz ICH Plus in optimizing care for patients with intracerebral hemorrhage (ICH). The study, “Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology,” highlights how AI-powered detection and quantification significantly reduced interhospital transfer (IHT) ti...

Viz.ai Launches New Strategic Alliance to Accelerate Timely Diagnosis and Deliver AI-Powered Precision Care for Patients with Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a new multi-year collaboration with Novartis aimed at transforming cancer care through the development of proprietary AI-powered workflows within the Viz Oncology Suite. This strategic alliance will focus on improving the identification and stratification of patients diagnosed with prostate and breast cancers based on key risk factors, accelerating...
Back to Newsroom